Eikance (atropine sulfate) eye drops (0.01%, 0.025%, and 0.05%) provide eye care professionals with flexible treatment options to manage progressive myopia when initiated in children aged 4–14 years.
Atropine treatment may be initiated in children when myopia progresses ≥ 0.5 diopters or axial length increases by 0.2 mm per year.1
Eikance eye drops have been developed to support evidence-based myopia control strategies. The product range offers a preservative-free, quality-controlled, sterile, and uniform pharmaceutical formulation that is available in convenient single-use ampoules.1
Before prescribing, please review the Product Information or call (AUS) 1300 659 646.
PBS Information: Eikance 0.01%, 0.025% and 0.05% are not listed on the Pharmaceutical Benefits Scheme.
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at.tga.gov.au/reporting-problems.
Reference
- Eikance Product Information.
